Skyline Medical, Inc. (NASDAQ: SKLN, SKLNU) is a medical device company engaged in the production and commercialization of an innovative, environmentally-friendly tool targeted at improving the safety of one of the most dangerous jobs in the medical field. The company’s proprietary STREAMWAY® system is a cost-effective, canister-free platform that eliminates the frequent and potentially hazardous interruptions commonly associated with surgical waste handling. Utilizing a direct-to-drain installation, Skyline’s technology greatly reduces the risk of hospital staff being exposed to biohazard fluids while simultaneously promoting improved patient-focused care and significant time savings.

The immense benefits of the STREAMWAY system have helped the company make considerable strides toward achieving sustainable market growth in recent years. Originally released in 2009, Skyline has sold 89 units to date, and the company expects this figure to rapidly expand as it looks to bolster sales and production efforts. As new hospitals continue to approve the use of the groundbreaking STREAMWAY system for additional applications, Skyline expects to significantly improve its financial results.

In the first quarter of 2015, Skyline successfully leveraged the marketability of its innovative system to promote strong financial growth. In addition to selling and shipping five STREAMWAY units, the company realized a 115 percent year-over-year increase in total revenues, recording $151,274 for the period. Likewise, Skyline’s net loss and total expenses were reduced by more than $1.3 million during the quarter, as compared to the previous year.

“Our sales increased year-over-year as we continue to make sales to large and diverse medical centers across a broader geographical area,” Josh Kornberg, chief executive officer of Skyline, stated in a news release. “We are optimistic about our business opportunities as we execute on our sales strategy.”

In recent weeks, Skyline has turned its attention toward increasing its market visibility and securing the capital necessary to continue progressing with its strategic business plan. The company recently announced a public offering that’s expected to raise approximately $15 million to fund its ongoing sales efforts while allowing Skyline to increase its product inventory in the future. These actions will be a key part of Skyline’s progress toward market growth, particularly as the company targets achieving profitability as early as next year.

For prospective shareholders, the increasingly widespread adoption of Skyline’s proprietary STREAMWAY technology could provide a platform for ongoing growth. Look for the company to benefit from an improved cash position following the completion of its upcoming public offering as it continues to build upon it recent progress in the future.

For more information, visit www.skylinemedical.com

In continued preparation for its planned uplisting to the NASDAQ Capital Market, Stellar Biotechnologies recently announced that it will proceed with a consolidation of its issued and outstanding shares on the basis of one post-consolidated common share for every 10 pre-consolidated shares, pending regulatory approval. The reverse split is intended to fulfill one of the quantitative requirements for listing on the NASDAQ exchange.

“The reverse stock split is a key step in our growth strategy,” Frank Oates, president and chief executive officer of Stellar, stated in a news release. “We believe that the proposed uplisting to the NASDAQ Capital Market offers a number of advantages including the opportunity to improve liquidity for our shareholders and to increase Stellar’s visibility in the broader investment community and with institutional investors.”

Although the reverse stock split was approved by Stellar’s board of directors on August 26, the company is currently awaiting approval from the Financial Industry Regulatory Authority and the TSX Venture Exchange before moving forward. With all required paperwork submitted, Stellar anticipates that the consolidation could become effective as early as next week.

If the company is successful in its efforts to uplist to the NASDAQ Capital Market, it will be in a strong strategic position to continue building on its recent financial performance. In its fiscal quarter ending June 30, Stellar recorded a 117 percent year-over-year increase in revenues on its way to achieving a net income of approximately $464,000.

As the leader in the sustainable manufacture of keyhole limpet hemocyanin (KLH), the company is benefitting from increased market demand as biotechnology firms continue to expand their pipelines of immunotherapies based on KLH protein. Following a strategic collaboration with Ostiones Guerreros SA de CV implemented earlier this year, Stellar has positioned itself as the only company with a reliable and scalable supply of KLH to meet this growing demand. As its roster of customers with successful therapeutic candidates approach FDA approval and commercialization, this advantage should provide an opportunity for the company to achieve rapid and sustainable market growth.

Stellar’s proposed move to the NASDAQ exchange is expected to significantly broaden its investment community, which could prove to be immensely beneficial as it looks to accelerate the development of its programs in response to rising market demand.

For more information, visit www.stellarbiotech.com

Catalyst Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of innovative therapies for people with rare debilitating diseases. The company’s lead product candidate, Firdapse®, recently completed a pivotal phase III clinical trial for the treatment of Lambert-Eaton myasthenic symdrome (LEMS), a rare neuromuscular, autoimmune disorder that afflicts about 3,000 people in the United States. Catalyst took a significant step toward the eventual commercialization of its innovative candidate when it initiated submission of a rolling new drug application (NDA) to the U.S. Food and Drug Administration (FDA) earlier this year. The company anticipates completing this submission during the fourth quarter, putting it on schedule for approval in the first half of 2016.

“[W]e have been working diligently to advance regulatory and commercial affairs and are pleased with the initiation of our rolling NDA submission to the FDA for Firdapse,” Patrick J. McEnany, chief executive officer of Catalyst, stated in a news release. “Additionally, we are on schedule with our key commercial strategic imperatives to support the successful launch of Firdapse.”

Catalyst’s development pipeline also includes CPP-115, which is being studied for the treatment of infantile spasms, epilepsy and other neurological conditions associated with reduced GABAergic signaling, such as post-traumatic stress disorder and Tourette’s disease. CPP-115 has been granted U.S. orphan drug designation by the FDA for the treatment of infantile spasms, making it eligible for a host of incentives designed to limit the costs associated with future development efforts.

In February, the company completed an offering of common stock that raised net proceeds of approximately $34.9 million to help fund its promising development programs. As of June 30, Catalyst reported cash and cash equivalents of $67.4 million with no outstanding debt. These considerable resources are expected to fund the company’s ongoing operations through the anticipated approval and subsequent product launch of Firdapse in 2016.

As it approaches the commercial launch of Firdapse, Catalyst is in a favorable position to promote strong financial growth. Look for the company to benefit from the operational flexibility afforded by its strong balance sheet as it focuses on making significant progress with the ongoing development of its product pipeline.

For more information, visit www.catalystpharma.com

Today before the opening bell, Latitude 360, Inc., the “ultimate upscale multi-dimensional entertainment eatery,” told investors that it has entered into management agreements for two locations of Revolutions, an upscale bowling, dining & entertainment concept owned by Frank Entertainment. The company intends to later acquire these two stores plus a third location in the near future via a Preferred Equity transaction.

The company expects these new locations to operate as Latitude 360 in the fourth quarter of this year. The move is part of Latitude 360’s expansion strategy and will effectively double the number of locations. The company has also entered into a letter of intent with Frank Entertainment to acquire these three locations. Assuming a definitive purchase agreement is entered into with the company and Frank Entertainment, it is the intent to close the acquisition of these three stores in the fourth quarter of 2015 subject to all closing conditions being met and liquor license approval being obtained from relevant government entities.

Latitude 360’s efforts are now focused on the integration and management of these locations and the September launch of 360 Fantasy Live, a cutting-edge daily fantasy sports platform. The Company expects that these strategic moves will provide a significant revenue increase and management believes will assist the Company as it positions itself for an uplisting to a national exchange in the future.

“We are confident the timing of the deal with Revolutions and 360 Fantasy Live’s upcoming launch made this the right move to create the most shareholder value for the capital outlay required. The decision to acquire existing locations will enable rapid top-line growth versus waiting for the construction of new location build-outs. We are excited about bringing the Latitude 360 to more markets as we continue to grow the revenues of our current locations,” said Brent Brown, CEO of Latitude 360.

Bruce Frank, President and CEO of Frank Entertainment, stated, “Latitude 360 is executing at the highest level in the restaurant entertainment space. The customer ‘360 Experience’ is one of the best concepts in the industry. We are excited to be a part of the momentum and look forward to more potential synergies with Frank Entertainment.”

In today’s press release, Latitude 360 also stated that it will not be moving forward with the previously announced construction and build out of the Albany, Kingston Collection or Shops at West End (Minneapolis) locations. The company executed mutual termination agreements on each location.

For more information, visit www.latitude360.com/corporate/investor-relations/

Let us hear your thoughts: Latitude 360, Inc. Message Board

Cherubim Interests is quickly gaining a foothold in the alternative construction, real estate development and controlled environment agriculture sectors.

Not only is this development-stage company focused on alternative construction projects, it also identifies mixed-use, single-family and multi-family properties for the purpose of real estate development, management and investment activities in North America. Within this sphere, the company is designed to cover the full spectrum of development from due diligence, acquisition and planning to construction, renovation and management. In short, Cherubim provides beginning-to-end development programs for single-family, multi-family and mixed use projects and properties.

Lately, the company has also explored opportunities that would highlight its focus on a third area of interest: the controlled environment agriculture sector. For some time now, the company has closely observed the cannabis industry’s progression and, after noting that more and more states were allowing for the recreational and medical use of cannabis, it began to look for an entry point into this marketplace and, recently, it found one.

Last month, Cherubim publicized that it had acquired an exclusive, worldwide license for a self-contained cultivation unit that would enable year-round plant cultivation in any location with water and electricity. Working in conjunction with its subsidiary BudCube Cultivation Systems, the company means to construct, deploy and lease marijuana plant cultivation facilities for commercial applications in states where the cultivation and consumption of medical and recreational cannabis is legal.

Cherubim’s licensed solution is set to provide growers with the opportunity to lease a portable and scalable turn-key cultivation solution. In so doing, the Cherubim team believes they can fill the gap for many first-time growers who want to enter the industry and for experienced cultivators without the capital to purchase land, construct the necessary facilities or improve pre-existing structures to create the ideal environment for cultivating a high-quality cannabis product.

For more information, visit the company’s website at http://CHIT.QualityStocks.net

Let us hear your thoughts: Cherubim Interests, Inc. Message Board

On the Move Systems today issued a press release to shine light on the problem of retailers investing millions of dollars in technology to ensure prompt order fulfillment only to see their efforts ruined by poor delivery service in the shipment’s “last mile,” leaving upset customers and destroying business relationships. On the Move Systems is focused on helping retailers fix that problem with its proposed shared economy courier service that promises not only fast, on-demand delivery, but professional, courteous service that will set it apart from traditional competition.

Amazon and Wal-Mart are two large retailers that realize the long-term value of providing fast, affordable last-mile solutions that satisfy customers’ expectations and add to the corporate bottom line. Each company is investing heavily to make sure their customers can not only get their online orders in the shortest possible time, but that those customers receive them in a way that leads to repeat business down the road.

“Wal-Mart and Amazon can afford to invest the millions to ensure last-mile satisfaction from the customer, but what about smaller retailers?” said OMVS CEO Robert Wilson. “Our on-demand courier business can help smaller retailers match Amazon’s and Wal-Mart’s speed, efficiency and service, putting them on an even footing with the giants. We expect there to be great demand for this, especially as the holiday season approaches and shippers face increasing lag times.”

Estimates peg the value of large last mile shipments at $8 billion annually, with the value of smaller shipments much higher. Retail industry analysts predict that companies that can best leverage last-mile solutions will be able to drive top-line growth and reap profits.

For more information on OMVS, please visit www.onthemovesystems.com

Let us hear your thoughts: On the Move Systems Corp. Message Board

ENGlobal, a leading provider of automation and engineering services, announced this morning that it has added two key professionals to its management team in newly created positions. The decision to expand its leadership team was made to support the company’s strategic commitment to further strengthen its midstream project execution and automation engineering businesses.

Mr. John Offutt will be serving as General Manager — Midstream Projects, with responsibility of the company’s Tulsa and Houston midstream operations. Mr. Offutt brings his knowledge and experience in managing all phases of large transportation-related projects, with the majority of his 30-year career having been with a major midstream operating company.

In his most recent assignment, Mr. Offutt managed a $700 million capital budget including 280 miles of pipeline and associated facilities. Mr. Offutt has directed teams of project managers, engineers, construction managers and support functions, being responsible for the successful execution of a lengthy list of both large and small diameter pipeline projects.

Mr. Robert Sammons will be serving as General Manager — Automation Engineering. In his role, Mr. Sammons will be expanding ENGlobal’s automation capabilities, in addition to supervising several of the company’s existing projects and technologies.

Mr. Sammons has gained extensive automation experience during his 25 year career, with senior level responsibilities focused on both business development and operations. Most recently he has been active in his own business providing Process Hazard Analysis and Burner Management Safety systems to midstream processing, refining and petrochemical clients.

“ENGlobal is privileged to include both John and Robert as senior professionals and members of the ENGlobal Team,” stated William A. Coskey, P.E., ENGlobal’s Chairman and Chief Executive Officer. “Our intent in the current market is to remain dynamic and proactive as a Company, building upon our many project execution skills and thereby demonstrating our continuous commitment to better serve our valued clients.”

For more information, visit www.ENGlobal.com

The Alkaline Water Company, Inc. (OTCQB: WTER) produces, distributes, markets and sells bottled alkaline water under the Alkaline88 brand. The company’s product, which is created using a proprietary electrolysis process, is an 8.8 pH-balanced bottled drinking water enhanced with trace minerals and electrolytes and specially formulated to promote a healthy, balanced lifestyle. With regular consumption, alkaline water products have been shown to provide a host of potential health benefits ranging from improved hydration levels to boosted immune system performance.

In recent months, WTER has focused on a national mass-market expansion program designed to increase the availability of Alkaline88 in retail locations across the United States. In its fiscal quarter ending June 30, these efforts translated into strong financial growth resulting from increased product distribution. The company’s total revenue for the quarter was just over $1.5 million, which represented a year-over-year increase of 164 percent. Building on this progress, WTER expects to achieve profitability in the fourth quarter of its current fiscal year.

“We see continued strong demand for our products at each of our retailers, and have already shipped over $1 million of product in our current second fiscal quarter,” Steven Nickolas, president and chief executive officer of WTER, stated in a news release. “With the addition of new retailers and increases in current store volumes, we expect to see significant sales growth over the next three quarters of fiscal 2016.”

The company’s most recently announced distribution agreement, which was unveiled last month, introduced the Alkaline88 brand to the Hawaiian Islands. Through this exclusive direct-to-store distribution deal with Hawaii-based Triple T Corporation, WTER secured a presence in both 7-Eleven convenience stores and Foodland grocery stores, which represent the largest operators in their respective categories across the island chain. The first order resulting from this agreement was for approximately 15,000 cases of product, and fast sell-through rates are expected to promote additional sizable orders in the future.

WTER’s considerable progress toward achieving profitability in recent months is a promising indication of its market potential in the years to come. For prospective shareholders, the company’s aggressive expansion efforts make it an intriguing investment opportunity. Look for WTER to continue leveraging the marketability of its Alkaline88 product in order to promote ongoing returns.

For more information, visit www.thealkalinewaterco.com

WRIT Media is focused on theatrical, mobile and interactive content, operating in the digital media industry as a holding company under two different divisions: content creation through Front Row Networks; and “retro” video gaming through Retro Infinity Inc. and Amiga Games Inc.

Front Row Networks was started to produce, acquire and distribute live concerts in 2D and 3D format initially for worldwide digital broadcast and eventually into digitally-enabled movie theaters. The subsidiary’s business model also calls for securing and distributing non-concert alternative theatrical programming, as well as the acquisition of rights for exclusive programming.

WRIT’s Retro Infinity subsidiary specializes in licensing classic computer and console video game libraries and adapts and republishes the most popular titles for smartphones, modern game consoles, micro-consoles, PCs and tablets. The company’s strategy is to leverage platform and classic game brands, along with proprietary technologies, to create new revenue from dormant but once-popular game libraries.

Amiga Games shares resources with Retro Infinity to adapt and republish the most popular titles from the Amiga family of computers for smartphones, modern game consoles, micro-consoles, PCs, and tablets. WRIT leverages the Amiga brand along with game brands of the past and proprietary technologies to create new revenue from classic games that with strong historical sales performance.

According to the Entertainment Software Association (ESA), the WRIT’s potential market stems from the 155 million Americans that play video games. As the industry continues to churn out new games that enable players to be more collaborative, the numbers of global participants rapidly grows. The ESA’s report also shows that frequent gamers (47%) find more value for their money in computer and video games than DVDs, movies and music.

By focusing on re-introducing popular games from the past, WRIT and its subsidiaries have the opportunity to cater to younger and older generations of gamers looking for both new and familiar game-playing challenges.

For more information, visit www.writmediagroup.com

Let us hear your thoughts: WRIT Media Group, Inc. Message Board

On the cusp of milestone TGA (Therapeutic Goods Administration) authorization in Australia to start clinical trials in its breakthrough Parkinson’s disease (PD) treatment using human parthenogenetic neural stem cells (hpNSCs), International Stem Cell Corp. (OTCQB: ISCO) was proud to show markets recently that the company has achieved a point of maturity where it is also driving home steadily increasing revenues. The release of the company’s Q2 2015 data also showed record net income for the quarter, with outlays decreasing due to having successfully wrapped on a number of important preclinical studies, even as revenues increased 14 percent year over year, and profit margins held steady at around 72 percent.

The company’s increasingly lucrative biomedical business and consistently profitable regenerative skin care offerings, administrated respectively via ISCO’s wholly-owned Lifeline Cell Technology and Lifeline Skin Care subsidiaries, continue to materially backstop the ongoing development of an exciting therapeutic pipeline based on proprietary human parthenogenetic stem cell (hpSC) technology which is efficient, perfect for commercial scale volumes, and also completely ethical. ISCO’s parthenogenesis technology employs a unique chemical stimulation technique for triggering unfertilized donor human eggs to create pluripotent cells that can then be differentiated through proprietary activation into numerous types of cells. From the aforementioned hpNSCs, which are increasingly seen via the company’s trial work as a paradigm shift approach when it comes to treating neurological system conditions like PD and even ischemic stroke. To liver and eye cells that can be used to effectively treat degenerative diseases affecting those tissue systems, such as metabolic liver disease and macular degeneration.

Just looking at the company’s application of hpNSCs in PD, we see a fundamentally new approach to therapy using transplanted stem cells, which could actually solve the underlying problems that give rise to such conditions, rather than just attempting to ameliorate the condition as with many other therapies, including the current standards of care. In PD, where injected hpNSCs actively differentiate into both dopaminergic neurons, as well as express brain-protecting neurotrophic factors, and thus directly address the two primary causes of debilitation, this approach shows its monumental superiority to other approaches by simultaneously replacing dead neurons and protecting any survivors. This kind of therapeutic solution constitutes an end-run on PD, and potentially many other diseases/disorders via a completely ethical, high-volume stem cell production technology, and it could make ISCO into one of the now $27 billion plus global stem cell market’s heaviest hitters.

Recent projections by Transparency Market Research indicate that the global stem cell market is just getting warmed up too. With around 24 percent CAGR seen occurring through 2018 and valuations the following year of as much as $119 billion or more, this highly fragmented market is primed for explosive growth. Something which is especially true for real innovators like ISCO, given that pluripotent stem cells are also seen as rapidly eclipsing the core adult stem cell type that currently has around 80 percent of the market share.

Perhaps even more importantly, the company’s UniStemCell bank, which is effectively the life science industry’s first commercial-scale aggregation of histocompatible, non-embryonic human stem cells, is ideally positioned to benefit from the continued upswing in the sector. Providing a growing logistical footprint of high-quality material for research purposes, as well as commercial applications. Moreover, ISCO has established a solid presence already here in the U.S., which is the epicenter of global activity for the stem cell industry due to federal government support for the sector. As the biobanking market expands further into Europe and other global markets, the company will benefit from first-mover advantages.

To take a closer look, visit www.internationalstemcell.com

Let us hear your thoughts: International Stem Cell Corp. Message Board